BNT162b2 (COMIRNATY)

BLA STN 125742/0

Response to 13 August 2021 CBER Information Request Regarding Duration of Follow-up in Study C4591001 (16+ Years of Age)

August 2021

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950317

TABLE OF CONTENTS

LIST OF TABLES

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950318

1. INTRODUCTION

Reference is made to BLA STN 125742/0 for the Pfizer-BioNTech COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age.

The purpose of this document is to respond to CBER's Information Request communicated from Captain Michael Smith, PhD (CBER) via email on 13 August 2021.

Below, CBER's comments/requests in ***bold italics*** are followed by the Sponsor's responses.

2. QUESTIONS

2.1. Question 1

Please complete the following table to describe follow-up time for the efficacy population.

Table. Blinded Follow-up Time after Dose 2, Phase 2/3 Participants 16 Years of Age and Older, Evaluable Efficacy Population

	Vaccine Group (as Randomized)		
	BNT162b2 N[a]=21047 n[b] (%)	Placebo N[a]=21210 n[b] (%)	Total N[a]=42257 n[b] (%)
Evaluable efficacy (7 days) population			
<2 Months			
≥2 Months to <4 Months			
≥4 Months to <6 Months			
≥6 Months			

Note: HIV-positive participants are not included in this summary because they are not included in the efficacy analyses.
a. N = number of participants in the analysis population for the primary efficacy endpoints (evaluable participants with and without evidence of prior infection). This value is the denominator for the percentage calculations
b. n = Number of subjects with the specified characteristic.

Response

Blinded follow-up time for participants 16 years of age and older in the evaluable efficacy population (evaluable participants with and without evidence of prior infection) is summarized in Table 1.

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950319

Table 1. Blinded Follow-up Time After Dose 2 – Phase 2/3 Subjects ≥16 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=21047) n[b] (%)	Placebo (N[a]=21210) n[b] (%)	Total (N[a]=42257) n[b] (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	840 (4.0)	910 (4.3)	1750 (4.1)
≥2 Months to <4 months	7411 (35.2)	7851 (37.0)	15262 (36.1)
≥4 Months to <6 months	11031 (52.4)	11158 (52.6)	22189 (52.5)
≥6 Months	1765 (8.4)	1291 (6.1)	3056 (7.2)

Note: Human immunodeficiency virus (HIV)-positive subjects are not included in this summary.
a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 13AUG2021 (16:37)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsl_fu_d2_p3_nohiv_ge16_eval

2.2. Question 2

Please provide the number of participants, by age cohort, who received placebo originally and opted not to receive BNT162b2 after unblinding.

Response

The disposition tables below were included in the Interim CSR for Study C4591001 6-Month Update and are based on the data cutoff date of 13 March 2021.

Pfizer/BioNTech is not able to determine the number of placebo participants who continued in the study until the time of unblinding and "opted" (ie, chose) not to receive BNT162b2, as differentiated from original placebo participants who had been unblinded but had not yet received BNT162b2 for other reasons (eg, had not attended a visit after unblinding).

With that caveat, as can be seen in Table 2, among participants 16-55 years of age, of the 13,132 participants originally randomized to placebo, 12,299 had been unblinded by the time of data cutoff (under the heading "Open-label follow-up period/Originally randomized to placebo"). Among these 12,299 participants, 11,405 had received a first dose of BNT162b2

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

at the time of data cutoff (labeled Dose 3 in Table 2), leaving a remainder of 894 participants originally randomized to placebo who had been unblinded but had not received BNT162b2 at the time of data cutoff. Among these 894 participants, 284 withdrew before receiving BNT162b2, and the other 610 either opted not to receive BNT162b2 or had not had the opportunity to receive BNT162b2 at the time of data cutoff.

Among participants >55 years of age (Table 3), of the 8948 participants originally randomized to placebo, 8649 had been unblinded by the time of data cutoff. Among these 8649 participants, 8207 had received a first dose of BNT162b2 at the time of data cutoff, leaving a remainder of 442 participants originally randomized to placebo who had been unblinded but had not received BNT162b2 at the time of data cutoff. Among these 442 participants, 213 withdrew before receiving BNT162b2, and the other 229 either opted not to receive BNT162b2 or had not had the opportunity to receive BNT162b2 at the time of data cutoff.

Table 2. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: 16-55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=13104) n[b] (%)	Placebo (N[a]=13132) n[b] (%)	Total (N[a]=26236) n[b] (%)
Randomized	13104 (100.0)	13132 (100.0)	26236 (100.0)
Not vaccinated	31 (0.2)	32 (0.2)	63 (0.2)
Original blinded placebo-controlled follow-up period			
Vaccinated	13073 (99.8)	13100 (99.8)	26173 (99.8)
Dose 1	13073 (99.8)	13100 (99.8)	26173 (99.8)
Dose 2	12802 (97.7)	12825 (97.7)	25627 (97.7)
Discontinued from original blinded placebo-controlled vaccination period[c]	278 (2.1)	388 (3.0)	666 (2.5)
Reason for discontinuation			
Lost to follow-up	132 (1.0)	128 (1.0)	260 (1.0)
Withdrawal by subject	81 (0.6)	117 (0.9)	198 (0.8)
No longer meets eligibility criteria	23 (0.2)	94 (0.7)	117 (0.4)
Adverse event	15 (0.1)	12 (0.1)	27 (0.1)
Pregnancy	6 (0.0)	6 (0.0)	12 (0.0)
Protocol deviation	2 (0.0)	6 (0.0)	8 (0.0)
Physician decision	3 (0.0)	4 (0.0)	7 (0.0)
Medication error without associated adverse event	2 (0.0)	1 (0.0)	3 (0.0)
Death	0	2 (0.0)	2 (0.0)
Withdrawal by parent/guardian	1 (0.0)	0	1 (0.0)
Other	13 (0.1)	18 (0.1)	31 (0.1)
Unblinded before 1-month post–Dose 2 visit	175 (1.3)	182 (1.4)	357 (1.4)

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950321

Table 2. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: 16-55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=13104) n[b] (%)	Placebo (N[a]=13132) n[b] (%)	Total (N[a]=26236) n[b] (%)
Completed 1-month post–Dose 2 visit	12586 (96.0)	12555 (95.6)	25141 (95.8)
Withdrawn from the study	259 (2.0)	349 (2.7)	608 (2.3)
Withdrawn after Dose 1 and before Dose 2	138 (1.1)	155 (1.2)	293 (1.1)
Withdrawn after Dose 2 and before 1-month post–Dose 2 visit	85 (0.6)	104 (0.8)	189 (0.7)
Withdrawn after 1-month post–Dose 2 visit	36 (0.3)	90 (0.7)	126 (0.5)
Reason for withdrawal from the study			
Lost to follow-up	150 (1.1)	160 (1.2)	310 (1.2)
Withdrawal by subject	88 (0.7)	147 (1.1)	235 (0.9)
Protocol deviation	3 (0.0)	20 (0.2)	23 (0.1)
Adverse event	6 (0.0)	3 (0.0)	9 (0.0)
Death	3 (0.0)	5 (0.0)	8 (0.0)
Physician decision	2 (0.0)	3 (0.0)	5 (0.0)
No longer meets eligibility criteria	1 (0.0)	2 (0.0)	3 (0.0)
Pregnancy	0	1 (0.0)	1 (0.0)
Medication error without associated adverse event	1 (0.0)	0	1 (0.0)
Withdrawal by parent/guardian	1 (0.0)	0	1 (0.0)
Other	4 (0.0)	8 (0.1)	12 (0.0)
Open-label follow-up period			
Originally randomized to BNT162b2	11858 (90.5)		
Received Dose 2/unplanned dose	61 (0.5)		
Completed 1-month post–Dose 2 visit	141 (1.1)		
Completed 6-month post–Dose 2 visit	3341 (25.5)		
Withdrawn from the study	58 (0.4)		
Withdrawn before 6-month post–Dose 2 visit	56 (0.4)		
Withdrawn after 6-month post–Dose 2 visit	2 (0.0)		
Reason for withdrawal from the study			
Withdrawal by subject	32 (0.2)		
Protocol deviation	17 (0.1)		
Lost to follow-up	3 (0.0)		
Physician decision	2 (0.0)		
Adverse event	1 (0.0)		
No longer meets eligibility criteria	1 (0.0)		
Other	2 (0.0)		
Originally randomized to placebo		12299 (93.7)	
Withdrawn from the study after unblinding and before Dose 3		284 (2.2)	
Received Dose 3 (first dose of BNT162b2 [30 µg])		11405 (86.8)	
Received Dose 4 (second dose of BNT162b2 [30 µg])		8586 (65.4)	

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950322

Table 2. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: 16-55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=13104) n[b] (%)	Placebo (N[a]=13132) n[b] (%)	Total (N[a]=26236) n[b] (%)
Discontinued from open-label vaccination period[d]		16 (0.1)	
Reason for discontinuation from open-label vaccination period			
Withdrawal by subject		5 (0.0)	
Pregnancy		4 (0.0)	
Adverse event		3 (0.0)	
Protocol deviation		3 (0.0)	
Lost to follow-up		1 (0.0)	
Completed 1-month post–Dose 4 visit		3424 (26.1)	
Withdrawn from the study		8 (0.1)	
Withdrawn after Dose 3 and before Dose 4		6 (0.0)	
Withdrawn after Dose 4 and before 1-month post–Dose 4 visit		2 (0.0)	
Withdrawn after 1-month post–Dose 4 visit		0	
Reason for withdrawal from the study			
Withdrawal by subject		7 (0.1)	
Protocol deviation		1 (0.0)	

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary but analyzed and reported separately.
Note: Subjects randomized but did not sign informed consent or had a significant quality event due to lack of PI oversight are not included in any analysis population.
Note: Because of a dosing error, Subjects C4591001 1081 10811053, C4591001 1088 10881077, C4591001 1177 11771089 and C4591001 1231 12311057 received an additional dose of BNT162b2 (30 µg) at an unscheduled visit after receiving 1 dose of BNT162b2 (30 µg) and 1 dose of placebo.
a. N = number of randomized subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
c. Original blinded placebo-controlled vaccination period is defined as the time period from Dose 1 to 1 month post–Dose 2.
d. Open-label vaccination period is defined as the time period from Dose 3 (first dose of BNT162b2 [30 µg]) to 1 month post–Dose 4 (second dose of BNT162b2 [30 µg]).
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:20) Source Data: adds Table Generation: 27MAR2021 (16:41)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output
File: ./nda2_unblinded/C4591001_BLA/adds_s002_age_p3_rand

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950323

Table 3. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: >55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=8981) n[b] (%)	Placebo (N[a]=8948) n[b] (%)	Total (N[a]=17929) n[b] (%)
Randomized	8981 (100.0)	8948 (100.0)	17929 (100.0)
Not vaccinated	24 (0.3)	18 (0.2)	42 (0.2)
Original blinded placebo-controlled follow-up period			
Vaccinated	8957 (99.7)	8930 (99.8)	17887 (99.8)
Dose 1	8957 (99.7)	8930 (99.8)	17887 (99.8)
Dose 2	8873 (98.8)	8825 (98.6)	17698 (98.7)
Discontinued from original blinded placebo-controlled vaccination period[c]	74 (0.8)	140 (1.6)	214 (1.2)
Reason for discontinuation			
Withdrawal by subject	28 (0.3)	64 (0.7)	92 (0.5)
Lost to follow-up	19 (0.2)	25 (0.3)	44 (0.2)
No longer meets eligibility criteria	3 (0.0)	26 (0.3)	29 (0.2)
Adverse event	12 (0.1)	14 (0.2)	26 (0.1)
Physician decision	2 (0.0)	4 (0.0)	6 (0.0)
Death	3 (0.0)	2 (0.0)	5 (0.0)
Protocol deviation	1 (0.0)	2 (0.0)	3 (0.0)
Medication error without associated adverse event	1 (0.0)	1 (0.0)	2 (0.0)
Other	5 (0.1)	2 (0.0)	7 (0.0)
Unblinded before 1-month post–Dose 2 visit	78 (0.9)	58 (0.6)	136 (0.8)
Completed 1-month post–Dose 2 visit	8796 (97.9)	8738 (97.7)	17534 (97.8)
Withdrawn from the study	84 (0.9)	135 (1.5)	219 (1.2)
Withdrawn after Dose 1 and before Dose 2	38 (0.4)	56 (0.6)	94 (0.5)
Withdrawn after Dose 2 and before 1-month post–Dose 2 visit	15 (0.2)	35 (0.4)	50 (0.3)
Withdrawn after 1-month post–Dose 2 visit	31 (0.3)	44 (0.5)	75 (0.4)
Reason for withdrawal from the study			
Withdrawal by subject	34 (0.4)	79 (0.9)	113 (0.6)
Lost to follow-up	24 (0.3)	31 (0.3)	55 (0.3)
Death	13 (0.1)	10 (0.1)	23 (0.1)
Protocol deviation	8 (0.1)	4 (0.0)	12 (0.1)
Adverse event	3 (0.0)	5 (0.1)	8 (0.0)
Physician decision	1 (0.0)	3 (0.0)	4 (0.0)
No longer meets eligibility criteria	0	2 (0.0)	2 (0.0)
Other	1 (0.0)	1 (0.0)	2 (0.0)
Open-label follow-up period			
Originally randomized to BNT162b2	8546 (95.2)		
Received Dose 2/unplanned dose	26 (0.3)		
Completed 1-month post–Dose 2 visit	69 (0.8)		

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950324

Table 3. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: >55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=8981) n[b] (%)	Placebo (N[a]=8948) n[b] (%)	Total (N[a]=17929) n[b] (%)
Completed 6-month post–Dose 2 visit	3073 (34.2)		
Withdrawn from the study	47 (0.5)		
Withdrawn before 6-month post–Dose 2 visit	47 (0.5)		
Withdrawn after 6-month post–Dose 2 visit	0		
Reason for withdrawal from the study			
Withdrawal by subject	24 (0.3)		
Protocol deviation	18 (0.2)		
Death	3 (0.0)		
Lost to follow-up	1 (0.0)		
Other	1 (0.0)		
Originally randomized to placebo		8649 (96.7)	
Withdrawn from the study after unblinding and before Dose 3		213 (2.4)	
Received Dose 3 (first dose of BNT162b2 [30 µg])		8207 (91.7)	
Received Dose 4 (second dose of BNT162b2 [30 µg])		7400 (82.7)	
Discontinued from open-label vaccination period[d]		8 (0.1)	
Reason for discontinuation from open-label vaccination period			
Protocol deviation		3 (0.0)	
Adverse event		2 (0.0)	
Death		2 (0.0)	
Lost to follow-up		1 (0.0)	
Completed 1-month post–Dose 4 visit		3785 (42.3)	
Withdrawn from the study		6 (0.1)	
Withdrawn after Dose 3 and before Dose 4		5 (0.1)	
Withdrawn after Dose 4 and before 1-month post–Dose 4 visit		0	
Withdrawn after 1-month post–Dose 4 visit		1 (0.0)	
Reason for withdrawal from the study			
Death		2 (0.0)	
Protocol deviation		2 (0.0)	
Adverse event		1 (0.0)	
Lost to follow-up		1 (0.0)	

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950325

Table 3. Disposition of All Randomized Subjects, by Age Group – Phase 2/3 Subjects ≥16 Years of Age Age Group: >55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=8981) n[b] (%)	Placebo (N[a]=8948) n[b] (%)	Total (N[a]=17929) n[b] (%)

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary but analyzed and reported separately.
Note: Subjects randomized but did not sign informed consent or had a significant quality event due to lack of PI oversight are not included in any analysis population.
Note: Because of a dosing error, Subjects C4591001 1081 10811053, C4591001 1088 10881077, C4591001 1177 11771089 and C4591001 1231 12311057 received an additional dose of BNT162b2 (30 µg) at an unscheduled visit after receiving 1 dose of BNT162b2 (30 µg) and 1 dose of placebo.
a. N = number of randomized subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
c. Original blinded placebo-controlled vaccination period is defined as the time period from Dose 1 to 1 month post–Dose 2.
d. Open-label vaccination period is defined as the time period from Dose 3 (first dose of BNT162b2 [30 µg]) to 1 month post–Dose 4 (second dose of BNT162b2 [30 µg]).
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:20) Source Data: adds Table Generation: 27MAR2021 (16:41)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA/adds_s002_age_p3_rand

2.3. Question 3

Please provide a breakdown of the subjects by age cohorts (young adults and older adults) who have ≥6 months of follow-up from Dose 2 to the earlier of discontinuation or the cutoff date, separately for the Safety and Evaluable Efficacy Populations. Please also provide a breakdown of these subjects, number of doses received and time of follow up after last dose.

Response

Follow-up time after Dose 2 by age cohorts for the Safety Population was summarized in the Interim CSR for Study C4591001 6-Month Update and is provided again below. In terms of total follow-up time (blinded placebo-controlled follow-up period, plus open-label follow-up from unblinding to the earlier of discontinuation or the cutoff date), in the original BNT162b2 group, 6666 participants 16-55 years of age (Table 4) and 5340 participants >55 years of age (Table 5) had ≥6 months of follow-up after Dose 2.

A similar summary of follow-up after Dose 2 is provided below for the evaluable efficacy population. In terms of total follow-up time, in the original BNT162b2 group, 6531 participants 16-55 years of age (Table 6) and 5232 participants >55 years of age

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950326

(Table 7) had ≥6 months of follow-up from Dose 2 to the earlier of discontinuation or the cutoff date.

Table 4. Follow-up Time After Dose 2, by Age Group – Phase 2/3 Subjects ≥16 Years of Age – Safety Population Age Group: 16-55 Years

	Vaccine Group (as Administered)		
	BNT162b2 (30 µg) (N[a]=13069) n[b] (%)	Placebo (N[a]=13095) n[b] (%)	Total (N[a]=26164) n[b] (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	917 (7.0)	962 (7.3)	1879 (7.2)
≥2 Months to <4 months	4448 (34.0)	4726 (36.1)	9174 (35.1)
≥4 Months to <6 months	6343 (48.5)	6327 (48.3)	12670 (48.4)
≥6 Months	1361 (10.4)	1080 (8.2)	2441 (9.3)
Total exposure from Dose 2 to cutoff date			
<2 Months	305 (2.3)		
≥2 Months to <4 months	552 (4.2)		
≥4 Months to <6 months	5546 (42.4)		
≥6 Months	6666 (51.0)		

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary but analyzed and reported separately.
a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:37)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output
File: ./nda2_unblinded/C4591001_BLA/adsl_fu_d2_age_p3_saf

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950327

Table 5. Follow-up Time After Dose 2, by Age Group – Phase 2/3 Subjects ≥16 Years of Age – Safety Population Age Group: >55 Years

	Vaccine Group (as Administered)		
	BNT162b2 (30 µg) (N^a=8957) n^b (%)	Placebo (N^a=8926) n^b (%)	Total (N^a=17883) n^b (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	334 (3.7)	369 (4.1)	703 (3.9)
≥2 Months to <4 months	3296 (36.8)	3344 (37.5)	6640 (37.1)
≥4 Months to <6 months	4910 (54.8)	4989 (55.9)	9899 (55.4)
≥6 Months	417 (4.7)	224 (2.5)	641 (3.6)
Total exposure from Dose 2 to cutoff date			
<2 Months	85 (0.9)		
≥2 Months to <4 months	127 (1.4)		
≥4 Months to <6 months	3405 (38.0)		
≥6 Months	5340 (59.6)		

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary but analyzed and reported separately.
a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 27MAR2021 (01:37)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output
File: ./nda2_unblinded/C4591001_BLA/adsl_fu_d2_age_p3_saf

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950328

Table 6. Follow-up Time After Dose 2, by Age Group – Phase 2/3 Subjects ≥16 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population
Age Group: 16-55 Years

	Vaccine Group (as Randomized)		
	BNT162b2 (30 µg) (N[a]=12424) n[b] (%)	Placebo (N[a]=12552) n[b] (%)	Total (N[a]=24976) n[b] (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	612 (4.9)	661 (5.3)	1273 (5.1)
≥2 Months to <4 months	4258 (34.3)	4592 (36.6)	8850 (35.4)
≥4 Months to <6 months	6201 (49.9)	6224 (49.6)	12425 (49.7)
≥6 Months	1353 (10.9)	1075 (8.6)	2428 (9.7)
Total exposure from Dose 2 to cutoff date			
<2 Months	54 (0.4)		
≥2 Months to <4 months	518 (4.2)		
≥4 Months to <6 months	5321 (42.8)		
≥6 Months	6531 (52.6)		

Note: Human immunodeficiency virus (HIV)-positive subjects are not included in this summary.
a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 13AUG2021 (16:50)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsl_fu_d2p3_nohiv_ge16_age_eval

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950329

Table 7. Follow-up Time After Dose 2, by Age Group – Phase 2/3 Subjects ≥16 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population Age Group: >55 Years

	BNT162b2 (30 µg) (N[a]=8623) n[b] (%)	Placebo (N[a]=8658) n[b] (%)	Total (N[a]=17281) n[b] (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	228 (2.6)	249 (2.9)	477 (2.8)
≥2 Months to <4 months	3153 (36.6)	3259 (37.6)	6412 (37.1)
≥4 Months to <6 months	4830 (56.0)	4934 (57.0)	9764 (56.5)
≥6 Months	412 (4.8)	216 (2.5)	628 (3.6)
Total exposure from Dose 2 to cutoff date			
<2 Months	12 (0.1)		
≥2 Months to <4 months	101 (1.2)		
≥4 Months to <6 months	3278 (38.0)		
≥6 Months	5232 (60.7)		

Note: Human immunodeficiency virus (HIV)-positive subjects are not included in this summary.
a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.
b. n = Number of subjects with the specified characteristic.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 13AUG2021 (16:50)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsl_fu_d2p3_nohiv_ge16_age_eval

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950330

2.4. Question 4

Please complete the following table to describe the updated VE at later time points periods, to supplement Table O provided with the VE shell tables in STN 125742.0.32.

Table O. Updated Vaccine Efficacy after Dose 1, Dose 1 All-Available Efficacy Population

Efficacy Endpoint Subgroup	BNT162b2 (N[a]=21909) Cases n1[b] Surveillance Time[c] (n2[d])	Placebo (N[a]=21908) Cases n1[b] Surveillance Time[c] (n2[d])	Vaccine Efficacy % (95% CI)[e]
First COVID-19 occurrence after Dose 1	128 8.155 (21385)	998 7.874 (21315)	87.6 (85.1, 89.8)
After Dose 1 to before Dose 2	43 1.273 (21385)	98 1.266 (21315)	56.4 (37.0, 70.3)
Dose 2 to 7 days after Dose 2	3 0.403 (21049)	30 0.401 (20952)	90 (68.0, 98.1)
≥7 Days after Dose 2	82 6.479 (21019)	870 6.207 (20901)	91 (88.7, 92.9)
≥7 Days after Dose 2 to <2 Months after Dose 2			
≥2 Months after Dose 2 to 4 Months after Dose 2			
≥4 Months after Dose 2			

Abbreviation: VE = vaccine efficacy.
[a] N = number of subjects in the specified group.
[b] n1 = Number of subjects meeting the endpoint definition.
[c] Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from Dose 1 to the end of the surveillance period.
[d] n2 = Number of subjects at risk for the endpoint.
[e] Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.

Response

Table 8 has been updated to describe VE at later time points.

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

FDA-CBER-2021-5683-0950331

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)

Table 8. Vaccine Efficacy – First COVID-19 Occurrence After Dose 1 – Blinded Placebo-Controlled Follow-up Period – Subjects ≥16 Years of Age – Dose 1 All-Available Efficacy Population

	Vaccine Group (as Randomized)					
	BNT162b2 (30 µg) (N[a]=21909)		Placebo (N[a]=21908)			
Efficacy Endpoint Subgroup	n1[b]	Surveillance Time[c] (n2[d])	n1[b]	Surveillance Time[c] (n2[d])	VE (%)	(95% CI[e])
First COVID-19 occurrence after Dose 1	128	8.155 (21385)	998	7.874 (21315)	87.6	(85.1, 89.8)
After Dose 1 to before Dose 2	43	1.273 (21385)	98	1.266 (21315)	56.4	(37.0, 70.3)
After Dose 1 to <11 days after Dose 1	38	0.643 (21385)	46	0.641 (21315)	17.6	(-29.4, 47.9)
≥11 Days after Dose 1 to before Dose 2	5	0.630 (21282)	52	0.625 (21254)	90.5	(76.3, 97.0)
Dose 2 to 7 days after Dose 2	3	0.403 (21049)	30	0.401 (20952)	90.0	(68.0, 98.1)
≥7 Days after Dose 2	82	6.479 (21019)	870	6.207 (20901)	91.0	(88.7, 92.9)
≥7 days after Dose 2 to <2 Months after Dose 2	12	2.786 (21019)	296	2.750 (20901)	96.0	(92.9, 98.0)
≥2 Months after Dose 2 to <4 Months after Dose 2	46	2.665 (20160)	446	2.564 (19720)	90.1	(86.5, 92.8)
≥4 Months after Dose 2	24	1.028 (12624)	128	0.893 (11760)	83.7	(74.7, 89.9)

Abbreviation: VE = vaccine efficacy.
a. N = number of subjects in the specified group.
b. n1 = Number of subjects meeting the endpoint definition.
c. Total surveillance time in 1000 person-years for the given endpoint across all subjects within each group at risk for the endpoint. Time period for COVID-19 case accrual is from Dose 1 to the end of the surveillance period.
d. n2 = Number of subjects at risk for the endpoint.
e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted for surveillance time.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (19:19) Source Data: adc19ef Table Generation: 06AUG2021 (08:58) (Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2 unblinded/C4591001 BLA Efficacy v2/adc19ef ve cov pd1 aai

FDA-CBER-2021-5683-0950332

Document Approval Record

Document Name:	Response to FDA re Duration of Follow-up 16+ in C4591001 - 16 August 2021
Document Title:	Response to FDA re Duration of Follow-up 16+ in C4591001 - 16 August 2021

Signed By:	Date(GMT)	Signing Capacity
Devlin, Carmel M	16-Aug-2021 18:07:41	Regulatory Affairs Approval
Perez, John	16-Aug-2021 18:27:30	Final Approval

090177e197d2750a\Approved\Approved On: 16-Aug-2021 18:27 (GMT)